These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9545478)

  • 1. Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR.
    Allison JW; James CA; Arnold GL; Stine KC; Becton DL; Bell JM
    Pediatr Radiol; 1998 Apr; 28(4):237-40. PubMed ID: 9545478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
    Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
    Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
    Poll LW; vom Dahl S; Koch JA; Börner D; Willers R; Cohnen M; Jung G; Scherer A; Niederau C; Häussinger D; Mödder U
    Rofo; 2001 Oct; 173(10):931-7. PubMed ID: 11588682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of Gaucher bone disease to enzyme replacement therapy.
    Poll LW; Maas M; Terk MR; Roca-Espiau M; Bembi B; Ciana G; Weinreb NJ
    Br J Radiol; 2002; 75 Suppl 1():A25-36. PubMed ID: 12036830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.
    Laudemann K; Moos L; Mengel KE; Lollert A; Reinke J; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Rofo; 2015 Dec; 187(12):1093-8. PubMed ID: 26200566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
    Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J; Szücs FZ; Benkö K; Maródi L
    Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy.
    Magnaldi S; Longo R; Ukmar M; Zanatta M; Bottega M; Sottocasa GL
    Eur Radiol; 1997; 7(4):486-91. PubMed ID: 9204325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity.
    Hermann G; Shapiro RS; Abdelwahab IF; Grabowski G
    Skeletal Radiol; 1993; 22(4):247-51. PubMed ID: 8316866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score.
    Robertson PL; Maas M; Goldblatt J
    AJR Am J Roentgenol; 2007 Jun; 188(6):1521-8. PubMed ID: 17515371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease.
    Hollak C; Maas M; Akkerman E; den Heeten A; Aerts H
    Blood Cells Mol Dis; 2001; 27(6):1005-12. PubMed ID: 11831867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume.
    Terk MR; Dardashti S; Liebman HA
    Skeletal Radiol; 2000 Oct; 29(10):563-71. PubMed ID: 11127678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaphyseal undertubulation in gaucher disease: resolution at MRI in a patient undergoing enzyme replacement therapy.
    Kelman CG; Disler DG
    J Comput Assist Tomogr; 2000; 24(1):173-5. PubMed ID: 10667678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
    Lollert A; Laudemann K; Mengel E; Hoffmann C; Moos L; Reinke J; Brixius-Huth M; Hennermann JB; Düber C; Staatz G
    Klin Padiatr; 2019 Mar; 231(2):52-59. PubMed ID: 30481833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
    Rosenthal DI; Doppelt SH; Mankin HJ; Dambrosia JM; Xavier RJ; McKusick KA; Rosen BR; Baker J; Niklason LT; Hill SC
    Pediatrics; 1995 Oct; 96(4 Pt 1):629-37. PubMed ID: 7567322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging and quantifying skeletal involvement in Gaucher disease.
    Maas M; Poll LW; Terk MR
    Br J Radiol; 2002; 75 Suppl 1():A13-24. PubMed ID: 12036829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status.
    Jaramillo D; Bedoya MA; Wang DJ; Pena AH; Delgado J; Jaimes C; Ho-Fung V; Kaplan P
    AJR Am J Roentgenol; 2015 Jun; 204(6):1296-302. PubMed ID: 26001241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy.
    Lorberboym M; Pastores GM; Kim CK; Hermann G; Glajchen N; Machac J
    J Nucl Med; 1997 Jun; 38(6):890-5. PubMed ID: 9189137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images.
    Mirowitz SA; Apicella P; Reinus WR; Hammerman AM
    AJR Am J Roentgenol; 1994 Jan; 162(1):215-21. PubMed ID: 8273669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.